Abbott Laboratories

Abbott Laboratories's next confirmed earnings release is scheduled for January 27, 2027.

As of March 31, 2026, Abbott Laboratories has 1.74B shares outstanding.

As of March 31, 2026, Abbott Laboratories maintains a current ratio of 1.39, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 64.60, indicating elevated leverage, while an interest coverage ratio of 20.28 demonstrates strong ability to service its debt obligations.

Over the twelve months ended March 31, 2026, Abbott Laboratories posted a return on equity (ROE) of 12.44, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 7.97 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 6.54, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 8.98, useful for judging operating efficiency across full business cycles. The company generates approximately 394,183.41 in revenue per employee across its workforce of 114,500.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.90 indicates how many times Abbott Laboratories sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, Abbott Laboratories recorded 1.86B in income tax expense. That works out to an effective tax rate of 22.87, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 8.14B, leaving 6.28B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on September 11, 2026, Abbott Laboratories's stock has declined approximately 22.17% over the past 52 weeks.

Over the twelve months ended March 31, 2026, Abbott Laboratories generated 45.13B in revenue and converted that into 6.28B in net income, yielding earnings per share of 3.59. EBITDA reached 10.87B, while operating income came in at 7.71B.

As of March 31, 2026, Abbott Laboratories holds 7.30B in cash and equivalents against 34.05B in total debt, resulting in a net debt position of 27.24B. Total book value stands at 52.06B, with working capital of 7.13B providing operational flexibility.

Abbott Laboratories produced 9.46B in operating cash flow over the twelve months ended March 31, 2026. After subtracting -2.09B in capital expenditures, free cash flow totaled 7.38B - equivalent to 4.24 per share.

Over the twelve months ended March 31, 2026, Abbott Laboratories posted a gross margin of 56.26, reflecting its pricing power and cost economics. The operating margin of 17.07 and net profit margin of 13.91 provide insight into operational efficiency.

Over the twelve months ended March 31, 2026, Abbott Laboratories paid dividends of 2.41 per share. The dividend payout ratio of 66.73 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth.

Abbott Laboratories's most recent stock split took place on June 1, 1998 with a 1:2 split ratio.